Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.47 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.47 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.47 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.47 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.47 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.47 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.47 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.47 |
| ▸ | CDK4 known ✓ | P11802 | 1/20 | 0.45 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.44 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4935425 | 1.00 | CHRNB2 (0.62) | CHRNB2CHRNA4PIM1PIM3ADRB1 | |
| SCHEMBL1992377 | 0.98 | CHRNB2 (0.64) | CHRNB2CHRNA4PIM1PIM3ADRB1 | |
| SCHEMBL5658694 | 0.92 | CHRNB2 (0.68) | CHRNB2CHRNA4PIM1PIM3 | |
| SCHEMBL25143036 | 0.88 | CHRNB2 (0.51) | CHRNB2CHRNA4PIM1PIM3ADRB1 | |
| Pivalate SCHEMBL28600103 | 0.84 | CHRNB2 (0.49) | CHRNB2CHRNA4PIM1PIM3ADRB1 | |
| Tert-Butyl Formate SCHEMBL27722336 | 0.82 | CHRNB2 (0.47) | CHRNB2CHRNA4PIM1PIM3ADRB1 | |
| SCHEMBL13779836 | 0.81 | MAPT (0.50) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL3367822 | 0.81 | CHRNB2 (0.47) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL29883782 | 0.81 | MAPT (0.50) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL823334 | 0.79 | MAPT (0.53) | CHRNB2CHRNA4KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752499-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2024-03-27 | — | — | EP | disclosed |
| CN-111770918-B | Inhibitors of TRPC6 | 勃林格殷格翰国际公司 | 2024-02-27 | — | — | CN | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| CN-111527078-B | Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors | 勃林格殷格翰国际公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-3700902-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2023-03-08 | — | — | EP | disclosed |
| US-11485740-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| EP-3786160-B1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-07-13 | — | — | EP | disclosed |
| US-20210163449-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-06-03 | — | — | US | disclosed |
| EP-3786160-A1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-03-03 | — | — | EP | disclosed |
| US-10889568-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-20200399282-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| EP-3752499-A1 | INHIBITORS OF TRPC6 | Boehringer Ingelheim International GmbH (DE) | 2020-12-23 | — | — | EP | disclosed |
| CN-111770918-A | Inhibitors of TRPC6 | 勃林格殷格翰国际公司 | 2020-10-13 | — | — | CN | disclosed |
| US-10800757-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| EP-3700902-A1 | PYRIDINE CARBONYL DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2020-09-02 | — | — | EP | disclosed |
| CN-111527078-A | Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors | 勃林格殷格翰国际公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2019158572-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399282-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC4 | ADRB1 280/4885HTR3E 297/4885HTR3B 260/4885 |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | ADRB1 168/4885HTR3E 397/4885HTR3B 292/4885 |
| US-20210163449-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | ADRB1 171/4885HTR3E 432/4885HTR3B 331/4885 |
| US-10889568-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | ADRB1 168/4885HTR3E 397/4885HTR3B 292/4885 |
| US-11485740-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC4 | ADRB1 280/4885HTR3E 297/4885HTR3B 260/4885 |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | ADRB1 168/4885HTR3E 397/4885HTR3B 292/4885 |
| US-10800757-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | ADRB1 168/4885HTR3E 397/4885HTR3B 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.